baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

ABBVIE INC. DL-,01/ US00287Y1091 /

30/04/2024 22:59:50	Chg. +1.320	Volume	Bid22:59:50	Ask22:59:50	Market Capitalization	Dividend Y.	P/E Ratio
151.680EUR	+0.88%	- Turnover: -	151.680Bid Size: -	152.300Ask Size: -	266.65 bill.EUR	-	-

GlobeNewswire 01/05 CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...

GlobeNewswire 30/04 CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings,...

GlobeNewswire 30/04 U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentratio...

GlobeNewswire 25/04 Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024

GlobeNewswire 25/04 Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...

GlobeNewswire 24/04 Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti...

GlobeNewswire 23/04 Leaders from Fortune 100 Best Companies to Work For To Share Insights at For All Summit May 7-9

GlobeNewswire 22/04 TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUS...

GlobeNewswire 22/04 Anthos Therapeutics Announces Appointment of Bill Meury as CEO

GlobeNewswire 19/04 NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes a...

GlobeNewswire 19/04 Life Science Cares Launches in Switzerland

GlobeNewswire 19/04 Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024

GlobeNewswire 19/04 Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable...

GlobeNewswire 18/04 Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial fo...

GlobeNewswire 17/04 Royalty Pharma Declares Second Quarter 2024 Dividend

GlobeNewswire 16/04 Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...

GlobeNewswire 16/04 OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of C...

GlobeNewswire 16/04 Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568

GlobeNewswire 15/04 Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessi...

Newsfile Corp 12/04 Allergan Aesthetics and University Lab Partners Announce the Golden Ticket Pitch Competition to Acce...

GlobeNewswire 09/04 STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DOMA, LABP, FUSN, ...

GlobeNewswire 09/04 Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

GlobeNewswire 08/04 Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual ...

GlobeNewswire 08/04 CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...

GlobeNewswire 06/04 Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Ca...

ABBVIE INC. DL-,01/ US00287Y1091 /

If you wish to receive reply to your feedback, please provide your email address.